Lum, L G <br/><br/>
Activated T-cell and bispecific antibody immunotherapy for high-risk breast cancer. Bench to bedside.  [electronic resource] 

 -  Acta haematologica  2001 
 - 130-6 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0001-5792 
<br/><br/><label>Standard No.: </label>10.1159/000046554  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Bispecific--therapeutic use<br/>Antigens, Neoplasm--immunology<br/>Breast Neoplasms--therapy<br/>CD3 Complex--immunology<br/>Cytokines--metabolism<br/>Cytotoxicity, Immunologic<br/>Drug Therapy, Combination<br/>Female<br/>Granulocyte-Macrophage Colony-Stimulating Factor--administration & dosage<br/>Humans<br/>Immunotherapy--methods<br/>Immunotherapy, Adoptive--methods<br/>Interleukin-2--administration & dosage<br/>Lymphocyte Activation--immunology<br/>Receptor, ErbB-2--immunology<br/>T-Lymphocytes--immunology<br/>T-Lymphocytes, Cytotoxic--metabolism<br/>Tumor Cells, Cultured